Mepolizumab biosimilar(DNARx)

N/A

Report date: 2025/03/07 17:33:51

Base Information

Drug NameMepolizumab biosimilar(DNARx)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionInterleukin-5 inhibitors
TargetsInterleukin-5
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDNARx LLC
China Registration ClassN/A

Develop Information

Active CompaniesDNARx LLC
Inactive CompaniesN/A
Active IndicationsAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A